Clinical trials: 2019-nCoV Pneumonia
Healthy
A Trial to Learn if a COVID-19 Therapeutic is Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants
The primary objective of the study is to evaluate the safety and tolerability of REGN14284 in healthy participants, as measured by all treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events…
- Trial name
- NCT05505448
- Testing
- REGN14284
- Where
- Belgium
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
COVID-19 (Coronavirus Disease 2019)
Physiological Finding in Management of COVID 19 Patients
This study utilizes physiological indicators of COVID-19 patients as tools for assessing, tracking, worsening, and improving the clinical symptoms of COVID-19 patients.
- Trial name
- COVID-19 (NCT07504341)
- Testing
- physiological parameters
- Where
- 2 sites in Taiwan
- Volunteers
- 15,000 people
- Sponsor
- St. Martin De Porress Hospital
Covid19, Sars-CoV-2 Infection
Post Acute Sequelae of COVID-19
COVID-19, a novel coronavirus, has caused widespread mortality and morbidity since it emerged in 2019. There is ongoing research and growing literature describing severe acute respiratory syndrome (SARS-COV-2).
- Conditions
- Covid19, Sars-CoV-2 Infection, Dyspnea Caused by 2019-nCoV, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- PASC (NCT04964115)
- Testing
- Cohort study
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Vanderbilt University Medical Center
Covid19
Analysis of the Pathophysiology and Pathology of Coronavirus Disease 2019 (COVID-19), Including Chronic Morbidity
NAPKON-HAP is the deep phenotyping platform of the National Pandemic Cohort Network (NAPKON) in Germany. NAPKON is a data and biospecimen collection of patients with COVID-19 and is part of the University Medicine Network (NUM)…
- Trial name
- NCT04747366
- Where
- 11 sites in Germany
- Volunteers
- 750 people
- Sponsor
- Charite University, Berlin, Germany
Coronavirus Disease 2019 (Covid19), Hematopoietic Neoplasms
Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)
The present study is a prospective phase IV study. All participants will receive the anti-Coronavirus Disease 2019 (COVID-19) Vaccine (messenger Ribonucleic acid-based vaccine, BNT162b2 or Comirnaty®, commercialized by…
- Trial name
- NCT04951323
- Testing
- anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Liege
COVID-19 (Coronavirus Disease 2019), COVID-19 Pandemic
University Hospital of Ioannina COVID-19 (Coronavirus Disease 2019) Registry
COVID-19 (Coronavirus Disease 2019) Registry of University Hospital of Ioannina. Retrospective datasource registry with quantitative and qualitative patient data from the hospital medical records.
- Conditions
- COVID-19 (Coronavirus Disease 2019), COVID-19 Pandemic, COVID-19 Pneumonia, COVID-19 Respiratory Infection
- Trial name
- NCT05534074
- Where
- Greece
- Volunteers
- 2,500 people
- Sponsor
- University Hospital, Ioannina
COVID-19
Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.
CALAVI will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.
- Trial name
- CALAVI (NCT04346199)
- Testing
- Acalabrutinib
- Where
- 50 sites in Argentina, Brazil and 12 more
- Volunteers
- 177 people
- Sponsor
- AstraZeneca
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Comparison of Non-invasive Oxygenation Strategies in Patients Admitted for Covid-19 Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome (ARDS) is the main clinical presentation of SARS-CoV-2 (Covid-19) infected patients admitted in Intensive Care Unit (ICU).
- Trial name
- SONIC-19 (NCT04725084)
- Testing
- Use of High Flow Nasal Cannula alone, Use of Non-invasive Ventilation, Use of Continuous Positive Airway Pressure
- Where
- 4 sites in France
- Volunteers
- 355 people
- Sponsor
- Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Sars-CoV2, Covid-19
Cardiac Arrest Incidence and Outcome Among Patients With COVID-19 in French ICUs
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the novel coronavirus disease 2019 (COVID-19) pandemic.
- Trial name
- ACICOVID (NCT04373759)
- Testing
- Cardiopulmonary resuscitation, Modified Rankin score
- Where
- 36 sites in France, Martinique
- Volunteers
- 186 people
- Sponsor
- Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
COVID-19
A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients
This open, multi-center, multiple ascending dose study was designed to evaluate the safety, tolerability, preliminary efficacy and PK/PD of BDB-001 injection in patients with mild, or general COVID-19.
- Trial name
- NCT05075304
- Testing
- BDB-001 injection
- Where
- 4 sites in China
- Volunteers
- 18 people
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
SARS-CoV-2 Infection
A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults
The primary objectives of this open-label trial were to evaluate the safety and pharmacokinetics (PK) of Anti-SARS-CoV-2 Immunoglobulin (Human) Investigational Product (COVID-HIG) administered intramuscularly (IM), subcutaneously…
- Trial name
- NCT05142306
- Testing
- COVID-HIG
- Where
- 2 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Covid19, Hydrogen-oxygen Gas
Hydrogen-Oxygen Generator With Nebulizer for Adjuvant Treatment of Novel Coronavirus Disease 2019 (COVID-19)
This is a multi-center, randomized, parallel controlled, double-blinded clinical trial to evaluate the effectiveness and safety of Hydrogen-Oxygen Generator with Nebulizer for adjuvant treatment of COVID-19 patients.
- Conditions
- Covid19, Hydrogen-oxygen Gas, AMS-H-03
- Trial name
- NCT05770206
- Testing
- Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03, OLO-1 Medical Molecular Sieve Oxygen Generator
- Where
- China
- Volunteers
- 218 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Acute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19
TD-0903 for ALI Associated With COVID-19
This Phase 2 study will evaluate the efficacy, safety, pharmacodynamics and pharmacokinetics of inhaled TD-0903 compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with confirmed…
- Trial name
- NCT04402866
- Testing
- TD-0903
- Where
- 24 sites in United States, Brazil and 5 more
- Volunteers
- 235 people
- Sponsor
- Theravance Biopharma
COVID-19 Infection
Clinical Characteristics and Prognostic Factors of Patients With COVID-19 (Coronavirus Disease 2019)
This is a multicenter, non-interventional, retrospective study using data captured in the EHRs (Electronic Health Records) of the participating hospital sites to determine factors that predict disease prognosis and outcomes in…
- Trial name
- NCT04569851
- Where
- 2 sites in Spain
- Volunteers
- 100,000 people
- Sponsor
- Savana Research
COVID-19 (Coronavirus Disease 2019)
A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe
The purpose of this study is to understand how COVID-19 affects people's ability to work and to calculate the costs associated with loss of work.
- Trial name
- NCT07072793
- Testing
- nirmatrelvir-ritonavir
- Where
- United States
- Volunteers
- 131,005 people
- Sponsor
- Pfizer
Pneumonia, Viral, Pneumonia, Ventilator-Associated
Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia
Serious Pneumonia and Critical Pneumonia caused by the 2019-nCOV infection greatly threats patients' life, UC-MSCs treatment has been proved to play a role in curing multiple diseases.
- Trial name
- NCT04269525
- Testing
- UC-MSCs
- Where
- China
- Volunteers
- 16 people
- Sponsor
- ZhiYong Peng
COVID-19, Viral Pneumonia
Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia
This single-center, prospective, open-label, comparator study, blind for central accessor evaluates the efficacy, safety of inhalations of low-doses of melphalan in patients with pneumonia with confirmed or suspected COVID-19.
- Trial name
- MICOV (NCT04380376)
- Testing
- Melphalan, Standard of care
- Where
- 2 sites in Russia
- Volunteers
- 60 people
- Sponsor
- Federal State Budgetary Institution, Pulmonology Scientific Research Institute
Coronavirus Disease 2019
Clinical Study on the Immune Program of Recombinant Novel Coronavirus（COVID-19) Vaccine (CHO Cell)
Popular topic：Clinical study on the immune program of recombinant Novel Coronavirus (COVID-19) vaccine (CHO cell). Research purpose:Main purpose: To evaluate the immunogenicity of recombinant novel coronavirus vaccine (CHO cells)…
- Trial name
- NCT05128643
- Testing
- Recombinant novel coronavirus vaccine (CHO cell)
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
2019 Novel Coronavirus Pneumonia
Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia
the investigators conduct a randomized, open-label trial to evaluate and compare the safety and efficacy of Xiyanping injection in patients with 2019-nCoV pneumonia.
- Trial name
- NCT04275388
- Testing
- Xiyanping injection, Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride
- Volunteers
- 426 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
SARS-CoV-2, Influenza, Human
Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)
The purpose of this clinical trial is to evaluate the safety, tolerability and efficacy of two doses (dose A and dose B) of Standardized Conditioned Medium Obtained by Coculture of M2-macrophages and fat-derived Mesenchymal…
- Conditions
- SARS-CoV-2, Influenza, Human, Respiratory Syncytial Virus Infections, Respiratory Distress Syndrome
- Trial name
- NCT06684379
- Testing
- PRS CK STORM
- Where
- 3 sites in Spain
- Volunteers
- 50 people
- Sponsor
- PEACHES BIOTECH